论文部分内容阅读
目的探讨相关肿瘤标志物组合在卵巢癌诊断中的应用价值。方法收集本院42例卵巢癌患者、75例良性卵巢疾病患者和50例健康体检者的静脉血,应用多肿瘤标志物蛋白芯片检测技术测定CA125、CEA、CA19-9、CA24-2等12种肿瘤标志物的含量,通过Logistic回归建立模型,绘制ROC曲线并计算曲线下面积来评价各肿瘤标志物的诊断价值。结果卵巢癌组的CA125、CEA、CA19-9、CA24-2、FER的检测结果及阳性率明显高于良性卵巢疾病组和健康体检组,差异有统计学差异(P<0.05)。其余肿瘤标志物在3组及2组间比较差异无统计学意义(P>0.05)。CA125、CEA、CA19-9、CA24-2的曲线下面积分别为0.796、0.693、0.726、0.652。4种肿瘤标志物联合检测曲线下面积为0.920,敏感性和特异性分别为88.81%和78.20%。结论单独检测CA125对卵巢癌的诊断有一定价值。CA125、CEA、CA19-9、CA24-2联合检测可为卵巢癌的临床诊断提供有效参考价值。
Objective To explore the value of the combination of related tumor markers in the diagnosis of ovarian cancer. Methods Venous blood samples from 42 patients with ovarian cancer, 75 patients with benign ovarian disease and 50 healthy subjects were collected. Twelve kinds of CA125, CEA, CA19-9 and CA24-2 were detected by multiple tumor marker protein microarray. Tumor markers, the establishment of the model by Logistic regression, draw ROC curve and calculate the area under the curve to evaluate the diagnostic value of each tumor marker. Results The positive rate of CA125, CEA, CA19-9, CA24-2 and FER in ovarian cancer group was significantly higher than that in benign ovarian disease group and healthy group (P <0.05). The remaining tumor markers in 3 and 2 groups showed no significant difference (P> 0.05). The area under the curve of CA125, CEA, CA19-9 and CA24-2 were 0.796,0.693,0.726,0.652. The area under the curve of the combined detection of four tumor markers was 0.920 with the sensitivity and specificity of 88.81% and 78.20% . Conclusion The detection of CA125 alone has some value in the diagnosis of ovarian cancer. The combined detection of CA125, CEA, CA19-9 and CA24-2 can provide effective reference value for the clinical diagnosis of ovarian cancer.